Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Lifesci Capital issued their Q2 2025 earnings per share (EPS) estimates for Dianthus Therapeutics in a research note issued to investors on Wednesday, June 18th. Lifesci Capital analyst R. Katkhuda anticipates that the company will post earnings per share of ($0.86) for the quarter. The consensus estimate for Dianthus Therapeutics' current full-year earnings is ($2.61) per share. Lifesci Capital also issued estimates for Dianthus Therapeutics' Q3 2025 earnings at ($0.87) EPS and Q4 2025 earnings at ($0.89) EPS.
A number of other analysts also recently issued reports on DNTH. Robert W. Baird decreased their target price on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating for the company in a research report on Tuesday, May 13th. Wedbush reaffirmed an "outperform" rating and issued a $36.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Guggenheim reaffirmed a "buy" rating and issued a $84.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a report on Tuesday, May 13th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Dianthus Therapeutics presently has an average rating of "Buy" and an average price target of $53.00.
View Our Latest Analysis on Dianthus Therapeutics
Dianthus Therapeutics Price Performance
NASDAQ:DNTH opened at $16.85 on Monday. The business has a fifty day simple moving average of $19.25 and a two-hundred day simple moving average of $20.83. Dianthus Therapeutics has a 1 year low of $13.37 and a 1 year high of $32.27. The company has a market capitalization of $541.90 million, a P/E ratio of -5.85 and a beta of 1.37.
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.86) by $0.04. Dianthus Therapeutics had a negative return on equity of 29.26% and a negative net margin of 1,544.23%. The business had revenue of $1.16 million during the quarter, compared to the consensus estimate of $0.81 million.
Institutional Investors Weigh In On Dianthus Therapeutics
Several large investors have recently added to or reduced their stakes in DNTH. US Bancorp DE boosted its stake in Dianthus Therapeutics by 2,013.3% during the first quarter. US Bancorp DE now owns 1,585 shares of the company's stock valued at $29,000 after buying an additional 1,510 shares during the period. KLP Kapitalforvaltning AS bought a new stake in Dianthus Therapeutics during the fourth quarter valued at $33,000. BNP Paribas Financial Markets bought a new stake in Dianthus Therapeutics during the fourth quarter valued at $59,000. GAMMA Investing LLC boosted its stake in Dianthus Therapeutics by 3,030.6% during the first quarter. GAMMA Investing LLC now owns 3,882 shares of the company's stock valued at $70,000 after buying an additional 3,758 shares during the period. Finally, AlphaQuest LLC boosted its stake in Dianthus Therapeutics by 273.1% during the fourth quarter. AlphaQuest LLC now owns 4,197 shares of the company's stock valued at $91,000 after buying an additional 3,072 shares during the period. Institutional investors own 47.53% of the company's stock.
About Dianthus Therapeutics
(
Get Free Report)
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Dianthus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dianthus Therapeutics wasn't on the list.
While Dianthus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
